Gastrin-Releasing Peptide and Glucose Metabolism Following Pancreatitis by Pendharkar, Sayali A. et al.
Articles © The authors   |   Journal compilation ©  Gastroenterol Res and Elmer Press Inc™   |   www.gastrores.org
This article is distributed under the terms of the Creative Commons Attribution Non-Commercial 4.0 International License, which permits 
unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited
224
Original Article  Gastroenterol Res. 2017;10(4):224-234
ressElmer 
Gastrin-Releasing Peptide and Glucose Metabolism 
Following Pancreatitis
Sayali A. Pendharkara, Marie Drurya, Monika Waliaa, Murray Korcb,  
Maxim S. Petrova, c
Abstract
Background: Gastrin-releasing peptide (GRP) is a pluripotent pep-
tide that has been implicated in both gastrointestinal inflammatory 
states and classical chronic metabolic diseases such as diabetes. Ab-
normal glucose metabolism (AGM) after pancreatitis, an exemplar in-
flammatory disease involving the gastrointestinal tract, is associated 
with persistent low-grade inflammation and altered secretion of pan-
creatic and gut hormones as well as cytokines. While GRP is involved 
in secretion of many of them, it is not known whether GRP has a role 
in AGM. Therefore, we aimed to investigate the association between 
GRP and AGM following pancreatitis.
Methods: Fasting blood samples were collected to measure GRP, 
blood glucose, insulin, amylin, glucagon, pancreatic polypeptide (PP), 
somatostatin, cholecystokinin, gastric-inhibitory peptide (GIP), gas-
trin, ghrelin, glicentin, glucagon-like peptide-1 and 2, oxyntomodulin, 
peptide YY (PYY), secretin, vasoactive intestinal peptide, tumor ne-
crosis factor-α (TNF-α), monocyte chemoattractant protein (MCP)-1, 
and interleukin-6. Modified Poisson regression analysis and linear re-
gression analyses were conducted. Four statistical models were used to 
adjust for demographic, metabolic, and pancreatitis-related risk factors.
Results: A total of 83 individuals after an episode of pancreatitis were 
recruited. GRP was significantly associated with AGM, consistently 
in all four models (P -trend < 0.05), and fasting blood glucose con-
tributed 17% to the variance of GRP. Further, GRP was significantly 
associated with glucagon (P < 0.003), MCP-1 (P < 0.025), and TNF-α 
(P < 0.025) - consistently in all four models. GRP was also signifi-
cantly associated with PP and PYY in three models (P < 0.030 for 
both), and with GIP and glicentin in one model (P = 0.001 and 0.024, 
respectively). Associations between GRP and other pancreatic and 
gut hormones were not significant.
Conclusion: GRP is significantly increased in patients with AGM 
after pancreatitis and is associated with increased levels of pro-in-
flammatory cytokines, as well as certain pancreatic and gut hormones. 
Detailed mechanistic studies are now warranted to investigate the ex-
act role of GRP in derangements of glucose homeostasis following 
pancreatitis.
Keywords: Gastrin-releasing peptide; Cytokines; Gut hormones; 
Pancreatic hormones; Post-pancreatitis diabetes mellitus
Introduction
Gastrin-releasing peptide (GRP) is a 27 amino acid peptide 
cleaved, along with neuromedin B and neuromedin C (which 
are related isoforms), from the 125 amino acid proGRP pre-
cursor [1]. This family of peptides, with a highly conserved 
sequence between species [2], binds to G-protein-coupled re-
ceptors with seven transmembrane domains. In humans, there 
are three receptor subtypes, two of which bind GRP with high 
affinity - GRP-receptor (GRP-R) and neuromedin-receptor [1]. 
The third receptor is an orphan bombesin receptor subtype-3 
(BRS-3) [3]. GRP binds preferentially to GRP-R, located pre-
dominantly in the pancreas, gastrointestinal tract, and central 
nervous system [2, 4], to play a role in numerous functions [4-
7]. For example, GRP acts as a proangiogenic factor and mi-
togen in certain cancers (in particular, small-cell lung cancer) 
[8]. It has also been reported to improve intestinal barrier func-
tion and oxidative stress, mitigate deleterious effects of sepsis, 
and decrease inflammation [2, 4]. Increased number of GRP-R 
has been observed in gastrointestinal inflammatory diseases 
such as chronic pancreatitis (in autopsied exocrine pancreatic 
parenchyma) and inflammatory bowel disease (in excised ileal 
tissue) [9-11]. GRP also has a stimulatory effect on secretion 
of pancreatic and gut hormones. Intravenous infusion of GRP 
in fasting state in healthy individuals results in dose-dependent 
increases in secretion of pancreatic polypeptide (PP), insulin, 
glucagon, gastrin, gastric-inhibitory peptide (GIP), and chol-
ecystokinin [6, 7, 12]. Further, emerging pre-clinical and clini-
cal evidence also shows that GRP is involved in regulation of 
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blood glucose homeostasis in diabetes mellitus (DM) [1, 5].
DM is a heterogeneous disease encompassing several dis-
orders characterized by persistent hyperglycemia. Diabetes of 
the exocrine pancreas is a recognized clinical condition [13, 
14] that may contribute to up to 10% of all diabetes in the 
Western population [15, 16] - a statistic based solely on new 
onset diabetes after chronic pancreatitis and pancreatic cancer. 
Yet, acute pancreatitis is the most common gastrointestinal dis-
ease resulting in hospital admission [17-19], and has the high-
est incidence rate of 33.74 cases (23.33 - 48.81) per 100,000 
person years worldwide compared to other pancreatic diseases 
[20]. There is an increasing body of evidence that nearly 40% 
of acute pancreatitis patients develop new onset diabetes after 
pancreatitis (NODAP) or new onset pre-diabetes [21] and that 
patients with one attack of acute pancreatitis are at a more than 
two times greater risk of developing NODAP than the gen-
eral population [22]. Furthermore, a recent population-based 
study showed that acute pancreatitis is the most common cause 
of diabetes of the exocrine pancreas with a prevalence of 78 
per 1,000 patients [23]. It is also worth noting that patients 
with abnormal glucose metabolism (AGM) after pancreatitis 
have altered secretion of certain pancreatic hormones (insu-
lin, PP, and amylin), gut hormones (oxyntomodulin, glicentin, 
and vasoactive intestinal peptide (VIP)), and pro-inflamma-
tory cytokines (interleukin-6 (IL-6), monocyte chemoattract-
ant proten-1 (MCP-1), and tumor necrosis factor-α (TNF-α)) 
[24-26]. While GRP may influence the secretion of pancreatic 
hormones, gut hormones, and cytokines, the evidence comes 
largely from pre-clinical studies and dates back to the 1980s 
[6, 7]. Whether this holds true for patients with AGM after 
pancreatitis in general and acute pancreatitis in particular, and 
whether GRP can be used as a marker of NODAP remains to 
be elucidated.
The primary aim of this study was to investigate the as-
sociation between GRP and AGM and the effect of potential 
confounders. The secondary aims were to study the associa-




The study was a cross-sectional study of patients after acute 
pancreatitis. The Health and Disability Ethics Committee (13/
STH/182) approved the study protocol.
Study population
Individuals were eligible for the study if they had 1) a primary 
diagnosis of acute pancreatitis based on two of the following 
three criteria: abdominal pain suggestive of acute pancreatitis 
and/or; characteristic radiological finding of acute pancreatitis 
on computerized tomography or ultrasound scan and/or; serum 
amylase and/or pancreatic amylase and/or lipase at least three 
times the upper limit of normal (amylase ≥ 405 U/L; pancre-
atic amylase ≥ 159 U/L; lipase ≥ 201 U/L) [27]; 2) were at 
least 18 years of age; 3) resided in Auckland at time of the 
study; and 4) provided informed consent. All eligible individu-
als were telephoned and invited to participate in the study. A 
certified phlebotomist conducted home visits for those partici-
pants unable to visit the hospital.
Individuals were not eligible for the study if they had/were 
pregnant, malignancy, post-endoscopic retrograde cholangio-
pancreatography pancreatitis, chronic pancreatitis, intraopera-
tive diagnosis of pancreatitis, or pre-diabetes or diabetes be-
fore the first hospital admission due to acute pancreatitis.
Definitions
Normal glucose metabolism (NGM) was defined as glycated 
hemoglobin A1c (HbA1c) ≤ 38 mmol/mol and/or fasting blood 
glucose (FBG) ≤ 5.5 mmol/L [13].
AGM was defined as newly developed pre-diabetes (HbA1c 
and/or FBG 39 - 47 mmol/mol and/or 5.6 - 6.9 mmol/L, respec-
tively) or diabetes (HbA1c and/or FBG ≥ 48 mmol/mol and/or 
≥ 7.0 mmol/L, respectively) after acute pancreatitis [13].
Body mass index (kg/m2) was determined using a medi-
cal scale with stadiometer. Participants were asked to remove 
any head attire and their shoes for height measurement, and 
to remove their shoes, jacket, belt, watch, and to empty their 
pockets of all items for weight measurement.
Etiology was classified, based on participant’s discharge 
notes, into the following three categories: 1) biliary; 2) alco-
hol-induced; and 3) other (including but not limited to hypertri-
glyceridemia, idiopathic pancreatitis, and pancreas divisum).
Severity of acute pancreatitis was determined in line with 
the 2012 Determinant-Based Classification [28].
Duration was defined as time (in months) from first attack 
of acute pancreatitis to the time of study.
Recurrence: participants admitted with more than one epi-
sode of confirmed acute pancreatitis at the time of the study 
deemed to have recurrent acute pancreatitis.
Sample acquisition and storage
All study participants were required to visit the clinic at 8:00 
am in a fasted state (at least 8 h). Participants were then taken 
to LabPlus, an International Accreditation New Zealand ac-
credited medical laboratory at Auckland City Hospital where a 
certified phlebotomist collected venous blood. Where required, 
appropriate preservatives/inhibitors (mentioned below) were 
added to the blood samples collected before allowing the blood 
to clot for at least 30 min before centrifugation. Blood was 
then centrifuged at 4 °C for 7.5 min at 4,000 g and plasma was 
separated and stored at -80 °C until use.
Laboratory assays
HbA1c, FBG, and insulin were analyzed at LabPlus, Auck-
land City Hospital using the boronate affinity chromatogra-
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phy assay (Trinity Biotech, Ireland), enzymatic colourimetric 
assay (F. Hoffmann-La Roche Ltd), and chemiluminescence 
sandwich immunoassay (Roche Diagnostics NZ Ltd), respec-
tively.
GRP, gastrin, somatostatin, cholecystokinin, GIP, glicen-
tin, glucagon-like peptide (GLP)-1, GLP-2, oxyntomodulin, 
VIP, and secretin were measured using the Merck-Millipore 
ELISA kits in accordance with the user’s manuals. Aprotinin 
was added into the initial collection step of all aforementioned 
hormones except GLP-1, to which the DPP-4 inhibitor was 
added. The Rayto Microplate Reader (V-2100 C, Santa Fe), 
with an absorbance range of 405 - 630 nm, was used. All re-
sults, except for glicentin, were reported in ng/mL. Glicentin 
was reported in pmol/L.
Glucagon (aprotinin), amylin (protease inhibitor cocktail), 
ghrelin (serine protease inhibitor), PP, peptide YY (PYY), IL-
6, MCP-1, and TNF-α were measured using the MILLIPLEX 
MAP Human metabolic hormone magnetic bead panel based 
on the Luminex xMAP technology. The Luminex xPONENT 
software quantified results (ng/mL) based on the recorded flu-
orescent reporter signals.
The intra- and inter-assay variation was < 10% and 15%, 
respectively.
Statistical analyses
All analyses were conducted using SPSS for Windows Version 
23 and P-values < 0.05 were considered statistically signifi-
cant.
The Chi-square test or student's t-test was used to inves-
tigate the differences in baseline characteristics between pa-
tients with NGM and AGM. Data were presented as frequency 
or mean ± standard deviation (SD), respectively.
A modified Poisson regression analysis was conducted to 
investigate the association between GRP and AGM. GRP was 
categorized into quartiles (quartile 1: 0 - 7.23 ng/mL; quartile 
2: 7.24 - 7.91 ng/mL; quartile 3: 7.92 - 8.21 ng/mL; and quar-
tile 4: ≥ 8.22 ng/mL) calculated using the frequency function. 
The P-trend was calculated by assigning each participant the 
median value in their quartile and assessing this as a continu-
ous variable. GRP was investigated as an independent variable 
in one unadjusted and three adjusted models [29]. Model 1 
was the unadjusted model and investigated the association be-
tween GRP and AGM. Model 2 was adjusted for demographics 
(age, sex, and ethnicity) and metabolic factors (BMI). Model 
3 was adjusted for variables included in model 2 as well as 
pancreatitis-related factors (etiology, severity of acute pan-
creatitis, duration since first attack of acute pancreatitis, and 
recurrence). Model 4 was adjusted for those variables found 
to be statistically significant in model 3. For these analyses, 
Pearson’s Chi-square was fit as the scale parameter, accounting 
for any overdispersion. The offset value was set as 1. For co-
variance matrix, a robust estimator was selected to derive the 
most robust estimates. In order to obtain the most conservative 
estimates, a main-effects model was fit for the one unadjusted 
and three adjusted models. Data were presented as prevalence 
ratios (PRs) with corresponding 95% confidence intervals 
(CIs) and P-values.
Further, having met all assumptions, linear regression 
analysis was conducted to investigate the association between 
each pancreatic hormone, gut hormone, and cytokine and GRP. 
Each pancreatic hormone, gut hormone, and cytokine was in-
vestigated as an independent variable in one unadjusted and 
three adjusted models (as above). Data were presented as β 
coefficients with corresponding 95% CI and P-values.
Results
Study population
Eighty-three individuals were recruited into the study. Men 
constituted 60% of the entire cohort. The average age of the 
study cohort was 51 ± 15 years. Of them, 30 (36%) developed 
AGM after pancreatitis, while 53 were normoglycaemic. None 
of the patients that developed AGM had family history of dia-
betes or received glucose-lowering medications. On average, 
the study participants were followed up after 30 months since 
their first attack of acute pancreatitis (Table 1).
The overall mean ± SD concentrations of each studied 
pancreatic hormone, gut hormone, and pro-inflammatory cy-
tokine were as follows: amylin, 14.32 ± 27.30; glucagon, 54.42 
± 50.26; insulin, 70.43 ± 48.42; PP, 80.12 ± 103.77; somato-
statin, 0.54 ± 0.52; cholecystokinin, 0.92 ± 0.39, GIP, 74.60 ± 
87.76; gastrin, 15,572.66 ± 21,845.67; ghrelin, 11.36 ± 10.41; 
glicentin, 12.64 ± 18.20; GLP-1, 6.76 ± 17.41; GLP-2, 7.01 ± 
5.44; oxyntomodulin, 15.06 ± 13.83; P YY, 99.61 ± 120.85; 
secretin, 0.15 ± 0.05; VIP, 0.52 ± 0.24; IL-6, 9.96 ± 23.73; 
MCP-1, 93.83 ± 72.37; and TNF-α, 5.15 ± 4.58.
Associations between GRP and glucose metabolism
GRP was significantly associated with AGM in all four mod-
els (Fig. 1). Compared with the lowest quartile, the PR (95% 
CI) of 4.31 (1.34, 13.84; P-trend = 0.017) in the highest quar-
tile differed most in model 4, followed by a PR of 3.70 (1.09, 
12.59; P-trend = 0.028) in model 2, a PR of 3.54 (1.19, 10.59; 
P-trend = 0.042) in model 1, and a PR of 3.35 (1.04, 10.82; P-
trend = 0.044) in model 3.
FBG and HbA1c independently contributed to 17.6% 
(Fig. 2a) and 2.5% (Fig. 2b) of circulating GRP variance, re-
spectively, in the study population.
Associations between GRP and pancreatic hormones
GRP decreased with a change in concentration of glucagon in 
all four models (Table 2). For every ng/mL change in gluca-
gon, GRP decreased by 0.005 ng/mL in models 3 and 4 (P < 
0.001), and by 0.004 ng/mL in models 1 (P = 0.001) and 2 (P 
= 0.002) (Table 2).
GRP decreased with a change in concentration of PP in 
the three adjusted models. For every ng/mL change in PP, GRP 
decreased by 0.002 ng/mL in models 2 (P = 0.010) and 3 (P < 
0.001), and by 0.001 ng/mL in model 4 (P = 0.028).
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Figure 1. Association between GRP and abnormal glucose metabolism in patients after acute pancreatitis. GRP: gastrin-releas-
ing peptide; CI: confidence interval; PR: prevalence ratio.
Table 1.  Baseline Characteristics of Study Participants
Characteristic NGM (n = 53) AGM (n = 30) Total (n = 83) P
Age (years)* 47 ± 15 57 ± 13 51 ± 15 0.005†
Sex 0.485
  Male 30 20 50
  Female 23 10 33
Ethnicity 0.005†
  NZ European 29 18 47
  Maori 1 5 6
  Pacific Islanders 2 1 3
  Asian 4 5 9
  Other 17 1 18
BMI (kg/m2)* 26.86 ± 4.82 29.93 ± 6.07 27.95 ± 5.46 0.016†
Etiology 0.906
  Biliary 24 13 37
  Alcohol 12 6 18
  Other 17 11 28
Recurrence 0.448
  No 40 20 60
  Yes 13 10 23
Severity < 0.001†
  Mild 50 18 68
  Moderate 2 9 11
  Severe/critical 1 3 4
Duration from first attack of AP (months)* 33 ± 30 23 ± 19 30 ± 27 0.112
FBG (mmol/L)* 4.98 ± 0.29 5.87 ± 0.77 5.30 ± 0.67 < 0.001†
HbA1c (mmol/mol)* 33.57 ± 2.62 39.13 ± 3.00 35.58 ± 3.84 < 0.001†
AGM: abnormal glucose metabolism; AP: acute pancreatitis; BMI: body mass index; FBG: fasting blood glucose; HbA1c: glycated hemoglobin A1c; 
NGM: normal glucose metabolism. *Data are presented as mean ± standard deviation (SD); †P-values < 0.05.
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No change in GRP concentration was observed with a 
change in concentrations of amylin, insulin, and somatostatin 
in any of the four models (Table 2).
Associations between GRP and gut hormones
GRP decreased with a change in concentrations of PYY, GIP, 
and glicentin in at least one model (Table 3). For every ng/mL 
change in PYY, GRP decreased by 0.002 ng/mL in models 3 
(P < 0.001) and 4 (P = 0.003), and by 0.001 ng/mL in model 2 
(P = 0.026).
GRP decreased with a change in concentrations of glicen-
tin and GIP in one adjusted model. For every ng/mL change 
in glicentin, GRP decreased by 0.007 ng/mL in model 3 (P = 
0.024). For every ng/mL change in GIP, GRP decreased by 
0.002 ng/mL in model 3 (P = 0.001).
No change in GRP concentration was observed with a 
change in concentrations of cholecystokinin, gastrin, ghrelin, 
GLP-1, GLP-2, oxyntomodulin, secretin, and VIP in any of the 
Figure 2. Associations between GRP and FBG (a) and HbA1c (b). FBG: fasting blood glucose; GRP: gastrin-releasing peptide; 
HbA1c: glycated hemoglobin A1c.
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four models (Table 3).
Associations between GRP and cytokines
GRP decreased with a change in concentrations of MCP-1 and 
TNF-α in all four models (Table 4). For every ng/mL change 
in MCP-1, GRP decreased by 0.003 ng/mL in models 2 (P = 
0.001) and 3 (P < 0.001), and by 0.002 ng/mL in models 1 (P 
= 0.017) and 4 (P = 0.024). For every ng/mL change in TNF-α, 
GRP decreased by 0.050 ng/mL in model 3 (P < 0.001), by 




β (95% CI) P
Amylin
  Model 1 -0.001 (-0.006, 0.005) 0.833
  Model 2 0.000 (-0.005, 0.004) 0.885
  Model 3 -0.001 (-0.005, 0.004) 0.793
  Model 4 0.000 (-0.005, 0.005) 0.972
Glucagon
  Model 1 -0.004 (-0.007, -0.002) 0.002*
  Model 2 -0.004 (-0.006, -0.002) 0.001*
  Model 3 -0.005 (-0.007, -0.003) < 0.001*
  Model 4 -0.005 (-0.007, -0.003) < 0.001*
Insulin
  Model 1 -0.001 (-0.004, 0.002) 0.602
  Model 2 0.001 (-0.002, 0.004) 0.420
  Model 3 0.002 (-0.001, 0.005) 0.249
  Model 4 0.001 (-0.002, 0.004) 0.509
Pancreatic polypeptide
  Model 1 -0.001 (-0.002, 0.001) 0.225
  Model 2 -0.002 (-0.003, 0.000) 0.010*
  Model 3 -0.002 (-0.003, -0.001) < 0.001*
  Model 4 -0.001 (-0.003, 0.000) 0.028*
Somatostatin
  Model 1 -0.022 (-0.311, 0.267) 0.881
  Model 2 -0.013 (-0.278, 0.253) 0.924
  Model 3 -0.075 (-0.323, 0.174) 0.557
  Model 4 -0.087 (-0.356, 0.183) 0.528
Data are presented as β coefficients (95% CI). *P-values < 0.05. Model 
1 was the unadjusted model. Model 2 was adjusted for age, sex, ethnic-
ity, and BMI. Model 3 was adjusted for age, sex, ethnicity, BMI, etiol-
ogy, severity, duration, and recurrence. Model 4 was adjusted for those 
confounders found to be significant in model 3. Specifically, model 4 for 
amylin and insulin was adjusted for BMI and recurrence. Model 4 for 
glucagon was adjusted for age, sex, BMI, recurrence, and duration. Mod-
el 4 for pancreatic polypeptide was adjusted for sex, age, BMI, and recur-
rence. Model 4 for somatostatin was adjusted for age and recurrence.




β (95% CI) P
Cholecystokinin
  Model 1 0.036 (-0.341, 0.413) 0.852
  Model 2 -0.050 (-0.410, 0.310) 0.785
  Model 3 -0.021 (-0.372, 0.330) 0.907
  Model 4 0.037 (-0.330, 0.404) 0.844
Gastric-inhibitory peptide
  Model 1 -0.001 (-0.002, 0.001) 0.223
  Model 2 -0.001 (-0.003, 0.000) 0.054
  Model 3 -0.002 (-0.004, -0.001) 0.001*
  Model 4 -0.001 (-0.003, 0.000) 0.065
Gastrin
  Model 1 0.000 (0.000, 0.000) 0.610
  Model 2 0.000 (0.000, 0.000) 0.463
  Model 3 0.000 (0.000, 0.000) 0.543
  Model 4 0.000 (0.000, 0.000) 0.677
Ghrelin
  Model 1 -0.011 (-0.025, 0.004) 0.142
  Model 2 -0.008 (-0.022, 0.007) 0.302
  Model 3 -0.012 (-0.026, 0.001) 0.077
  Model 4 -0.010 (-0.024, 0.005) 0.180
Glicentin
  Model 1 -0.005 (-0.012, 0.002) 0.175
  Model 2 -0.006 (-0.013, 0.001) 0.081
  Model 3 -0.007 (-0.014, -0.001) 0.024*
  Model 4 -0.004 (-0.010, 0.003) 0.282
Glucagon-like peptide-1
  Model 1 0.001 (-0.001, 0.002) 0.322
  Model 2 0.000 (-0.001, 0.002) 0.845
  Model 3 0.000 (-0.001, 0.002) 0.754
  Model 4 0.000 (-0.001, 0.002) 0.588
Glucagon-like peptide-2
  Model 1 0.022 (-0.010, 0.054) 0.181
  Model 2 0.017 (-0.015, 0.048) 0.300
  Model 3 0.016 (-0.015, 0.046) 0.318
  Model 4 0.021 (-0.009, 0.051) 0.175
Oxyntomodulin
  Model 1 0.005 (-0.007, 0.017) 0.403
  Model 2 0.001 (-0.010, 0.013) 0.839
  Model 3 0.001 (-0.010, 0.012) 0.840
  Model 4 0.004 (-0.007, 0.016) 0.464
Peptide YY
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0.039 ng/mL in model 4 (P = 0.008), by 0.036 ng/mL in model 
2 (P = 0.015), and by 0.034 ng/mL in model 1 (P = 0.023).
No change in GRP concentration was observed with a 
change in concentration of IL-6 in any of the four models (Ta-
ble 4).
Discussion
GRP has been implicated in glucose homeostasis and in chronic 
inflammatory diseases such as chronic pancreatitis and inflam-
matory bowel disease in animal and clinical studies. However, 
this is the first clinical study to investigate GRP as a marker of 
AGM in patients following an episode of acute pancreatitis. 
The findings of this study show that GRP is elevated in pa-
tients with AGM after acute pancreatitis and FBG contributes 
to nearly a fifth of the variance in circulating GRP levels. GRP 
was also found to be significantly associated with glucagon in 
the unadjusted and three adjusted models, and with PP, PYY, 
GIP, glicentin, MCP-1, and TNF-α in at least one adjusted 
model. These findings have important translational implica-
tions and may help devise strategies for the timely identifica-
tion of individuals with NODAP.
The role of GRP in glucose homeostasis is complex given 
its expression in the pancreas, gastrointestinal tract, adipose 
tissue, and central nervous system [30, 31]. Pre-clinical and 
clinical studies over the past three decades have demonstrated 
that GRP stimulates the secretion of pancreatic hormones and 
gut hormones. In the pancreas, GRPergic neurons innervate 
the islet cells and GRP interacts with the receptors present on 
the basolateral membranes of these cells to release digestive 
enzymes. Moreover, the endocrine islet cells express GRP-R, 
and intra-pancreatic release of GRP by GRPergic neurons has 
the potential to stimulate the release of hormones such as insu-
lin, glucagon, somatostatin, and PP [12]. While several studies 
have investigated to various extents the role of certain pancre-
atic and gut hormones in diabetes of the exocrine pancreas, 
what mediates the changes in these hormones and ultimately 
results in NODAP has never been investigated. A recent pre-
clinical study by Jha et al examined the effects of intracer-
ebroventricularly administered GRP on glucose metabolism 
[5]. The authors showed that administration of GRP resulted 
in persistent hyperglycemia and this was attributed largely to 
enhanced endogenous glucose production - increased glycog-
enolysis and/or gluconeogenesis [5]. However, findings from 
other in vivo studies in rats, mice, and humans showed that 
GRP potentiates insulin secretion [5, 6, 32-34]. Based on this 
evidence, and the peripheral and central distribution of GRP 
neurons, Jha et al concluded that “centrally” administered GRP 
stimulates glucagon release. A clinical study by Wood et al [6], 




β (95% CI) P
Interleukin-6
  Model 1 -0.001 (-0.006, 0.005) 0.749
  Model 2 -0.004 (-0.009, 0.002) 0.211
  Model 3 -0.005 (-0.010, 0.001) 0.108
  Model 4 0.000 (-0.006, 0.005) 0.901
Monocyte chemoattract protein-1
  Model 1 -0.002 (-0.004, 0.000) 0.024*
  Model 2 -0.003 (-0.005, -0.001) 0.001*
  Model 3 -0.003 (-0.005, -0.002) < 0.001*
  Model 4 -0.002 (-0.004, 0.000) 0.017*
Tumor necrosis factor-α
  Model 1 -0.034 (-0.063, -0.005) 0.023*
  Model 2 -0.036 (-0.065, -0.007) 0.015*
  Model 3 -0.050 (-0.078, -0.023) < 0.001*
  Model 4 -0.039 (-0.069, -0.010) 0.008*
Data are presented as β coefficients (95% CI). *P-values < 0.05. Model 
1 was the unadjusted model. Model 2 was adjusted for age, sex, ethnic-
ity, and BMI. Model 3 was adjusted for age, sex, ethnicity, BMI, etiol-
ogy, severity, duration, and recurrence. Model 4 was adjusted for those 
confounders found to be significant in model 3. Model 4 for interleukin-6 
was adjusted for BMI and recurrence. Model 4 for monocyte chem-
oattractant protein-1 was adjusted for BMI, recurrence, and duration. 




β (95% CI) P
  Model 1 -0.001 ( -0.002, 0.000) 0.055
  Model 2 -0.001 (-0.002, 0.000) 0.026*
  Model 3 -0.002 (-0.003, -0.001) < 0.001*
  Model 4 -0.002 (-0.003, -0.001) 0.003*
Secretin
  Model 1 0.088 (-2.688, 2.845) 0.950
  Model 2 -0.390 (-2.994, 2.215) 0.769
  Model 3 -0.932 (-3.560, 1.696) 0.487
  Model 4 -0.097 (-2.722, 2.528) 0.942
Vasoactive intestinal peptide
  Model 1 0.351 (-0.271, 0.973) 0.269
  Model 2 0.245 (-0.343, 0.833) 0.414
  Model 3 0.367 (-0.253, 0.987) 0.246
  Model 4 0.497 (-0.082, 1.076) 0.092
Data are presented as β coefficients (95% CI). *P-values < 0.05. Model 
1 was the unadjusted model. Model 2 was adjusted for age, sex, ethnic-
ity, and BMI. Model 3 was adjusted for age, sex, ethnicity, BMI, etiol-
ogy, severity, duration, and recurrence. Model 4 was adjusted for those 
confounders found to be significant in model 3. Specifically, model 4 for 
cholecystokinin, gastric-inhibitory peptide, gastrin, ghrelin, glucagon-
like peptide-1 and 2, oxyntomodulin, secretin, and vasoactive intestinal 
peptide was adjusted for BMI and recurrence. Model 4 for glicentin was 
adjusted for BMI, recurrence, and duration. Model 4 for peptide YY was 
adjusted for age, BMI, recurrence, and duration.
Table 3.  Associations Between Gastrin-Releasing Peptide and 
Gut Hormones - (continued)
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involving six healthy volunteers, investigated the effect of in-
travenous GRP infusions on fasting and postprandial glucose 
levels and pancreatic hormones, namely insulin, glucagon, and 
PP. While GRP was found to have no effect on basal insulin 
secretion, it was shown to enhance glucose-dependent insulin 
secretion. Glucagon and PP levels did not change upon GRP 
infusion [6]. By contrast, a study by Knigge et al [7], also 
involving six healthy individuals, reported that PP levels in-
creased by two to four times upon GRP infusion in a dose-de-
pendent manner. Both plasma glucagon and insulin levels were 
also found to be elevated upon GRP infusion while no change 
was noted in basal glucose levels [7]. The study by Knigge et 
al also reported elevated gastrin concentration in response to 
GRP infusion and the authors speculated that GRP stimulates 
antral G-cells to stimulate gastrin secretion, which in turn acts 
on pancreatic islet cells to release pancreatic hormones [7]. 
However, our study found no association between GRP and 
gastrin, suggesting that GRP independently regulates glucose 
homeostasis via the GRP-R present on the islet cells than via 
the gastrin-mediated pathway. Findings from our study show, 
for the first time, that GRP levels are increased in patients with 
AGM after acute pancreatitis and that FBG contributes more 
than 17% to circulating GRP variance. These findings are a 
step further towards understanding the intricate and complex 
pathophysiological mechanisms of glucose derangements in 
diseases of the exocrine pancreas.
While insulin resistance and compensatory hyperinsu-
linemia are the primary pathogenetic mechanisms of glucose 
derangements after acute pancreatitis [24, 35-40], recent evi-
dence also suggests that the elevated insulin levels in blood 
might be attributed to impaired insulin clearance [41]. This 
is relevant to the findings of the present study, which showed 
consistently no association between GRP and insulin in any of 
the four models but did show consistently significant associa-
tion between GRP and glucagon in all the models. It is well 
established that glucagon secretion is inversely related to insu-
lin secretion in pancreatic islets, and that they have opposing 
effect on circulating blood glucose levels [42]. That GRP was 
not associated with insulin was a novel finding as evidence to 
date suggests that GRP stimulates glucose-dependent insulin 
secretion by acting directly on the pancreatic islet cells [30]. 
This could be due to the possibility that in individuals with 
AGM after acute pancreatitis, the GRP and glucagon pathway 
is preserved, while the insulin pathway is compromised. The 
reasons for this imbalance are not readily evident. It is unlike-
ly that this could be attributed to desensitized GRP-R on the 
pancreatic islets since this would compromise both insulin and 
glucagon secretion. Instead, it is possible that the inflamma-
tory cytokines cause some insulin resistance in target tissues 
with an inadequate beta cell response. In such a setting, per-
sistent alpha cell activity could exacerbate the hyperglycemia. 
Whether the elevation in blood glucose levels was due to gly-
cogenolysis or gluconeogenesis, however, could not have been 
investigated in this study as endogenous glucose production 
was not measured. GRP is also thought to stimulate insulin se-
cretion by modulating PP [30]. PP has previously been investi-
gated in diseases of the exocrine pancreas, with studies involv-
ing chronic pancreatitis patients with and without diabetes, as 
well as patients with AGM after acute pancreatitis, showing 
decreased meal-induced and/or fasting PP levels [43-45]. It is 
likely that the GRP and PP pathway is impaired in individuals 
with AGM associated with diseases of the exocrine pancreas 
and that not only decreased PP levels but also elevated GRP 
levels may be hallmarks of NODAP. This hypothesis needs to 
be investigated in carefully designed mechanistic studies.
To date, the role of gut hormones, such as GLP-1, GIP, 
and PYY, has been well investigated in the setting of type 2 
diabetes but evidence on the role of these hormones in the 
setting of NODAP is limited [46]. A recently published study 
showed that incretins were detectable in 90% of patients after 
pancreatitis in a fasted state [25]. Given that the effect of food 
intake was ruled out, it was suggested that other triggers, such 
as neuropeptides, must have influenced the circulating levels 
of gut hormones. GRP may fit the bill as this study showed for 
the first time that GRP is significantly associated with PYY 
and glicentin. Glicentin, produced in the gut L-cells and cen-
tral nervous system (brainstem), and containing sequences 
of glucagon, is known to stimulate insulin secretion [47, 48]. 
However, a recent study showed that glicentin levels are de-
creased in patients with AGM after acute pancreatitis [25]. It 
is possible that the decrease in glicentin levels results in com-
pensatory elevated GRP levels or vice versa. Yet, it is difficult 
to determine the exact role of glicentin and its association with 
GRP in AGM after acute pancreatitis as its actions appear to be 
similar to those of glucagon and GLP-1 [46]. P YY, a member 
of the PP family, was found to be significantly associated with 
pro-inflammatory cytokines - IL-6, MCP-1, and TNF-α, in pa-
tients after acute pancreatitis [26]. In the present study, PYY 
was also found to be significantly associated with GRP, which 
in turn was associated with MCP-1 and TNF-α. Furthermore, 
there is a known bi-directional relationship between the im-
mune system and nervous system, with peptides such as neu-
ropeptide Y and GRP playing a crucial role [26, 49].
This study has several strengths. First, this is the largest 
clinical study to investigate the role of GRP and its associa-
tions with a comprehensive panel of pancreatic hormones, 
gut hormones, and the major pro-inflammatory cytokines in 
defective glucose homeostasis associated with diseases of the 
exocrine pancreas. Second, the study had a relatively homog-
enous population of patients after acute pancreatitis - an acute 
inflammatory disease and the largest contributor to deranged 
glucose metabolism associated with diseases of the exocrine 
pancreas [23]. Third, multi-level statistical modeling was used 
and several patient-, metabolism-, and pancreatitis-related 
characteristics were adjusted for in order to derive the most 
robust estimates. The study also has several limitations. First, 
only circulating insulin levels in blood were measured, which 
may not estimate insulin secretion accurately. Detailed pheno-
typing studies, such as hyperglycemic-euglycemic clamps, are 
now warranted to measure insulin secretion precisely. Also, 
to determine whether or not GRP stimulates insulin secretion, 
future studies should administer exogenous GRP at varying 
doses and investigate its effect on insulin level. Second, while 
our study showed elevated GRP levels in patients with AGM 
after acute pancreatitis, and that FBG contributed to 17% of 
variance in GRP levels, it is not known whether FBG stimu-
lates increased GRP secretion or vice versa. Use of high-per-
formance liquid chromatography glucose tracer is warranted in 
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future studies to measure endogenous glucose production upon 
administration of GRP [50]. Third, we did not use synthetic 
GRP analogues/ligands to elucidate whether the increased cir-
culating GRP levels were in response to AGM in patients after 
acute pancreatitis or desensitized GRP-R on the pancreatic is-
let cells. Last, we did not measure other ligands known to bind 
to GRP-R (albeit with less affinity), in particular neuromedin 
B and neuromedin C, which may explain the elevated circulat-
ing GRP levels observed in this study [51].
In conclusion, GRP appears to be a misnomer, at least in 
the setting of pancreatitis. It does not increase the circulating 
levels of gastrin but rather is a mediator involved in derange-
ments of glucose homeostasis following pancreatitis. The latter 
is evidenced by increased GRP levels in patients with AGM, 
its association with certain pancreatic and gut hormones, as 
well as pro-inflammatory cytokines, all of which have been 
implicated in NODAP. It is also worth noting that FBG inde-
pendently contributes to nearly a fifth of circulating GRP lev-
els. Future studies are now warranted to gain further insights 
into the role of GRP in diseases of the exocrine pancreas.
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